Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOCOL-01 Induction Chemotherapy + Concurrent Chemoradiotherapy in Cervical Cancer With Para-aortic Lymph Node Involvement
2024-513576-18-00Phase 3Suspended
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in Cervical Cancer (CC) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Overall survival. Started May 2024; status: suspended.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-513576-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513576-18-00.